Skip to main content
JCI Insight logoLink to JCI Insight
. 2019 Feb 21;4(4):e127684. doi: 10.1172/jci.insight.127684

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Alfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, Simon F Lacey, Jan Joseph Melenhorst, Maria Krevvata, Martin P Carroll, William H Matsui, Qiuju Wang, Madhav V Dhodapkar, Kavita Dhodapkar, Rituparna Das, Dan T Vogl, Brendan M Weiss, Adam D Cohen, Patricia A Mangan, Emily C Ayers, Selene Nunez-Cruz, Irina Kulikovskaya, Megan M Davis, Anne Lamontagne, Karen Dengel, Naseem DS Kerr, Regina M Young, Donald L Siegel, Bruce L Levine, Michael C Milone, Marcela V Maus, Carl H June
PMCID: PMC6478404  PMID: 30830874

Original citation: JCI Insight. 2018;3(8):e120505. https://doi.org/10.1172/jci.insight.120505

Citation for this corrigendum: JCI Insight. 2019;4(4):e127684. https://doi.org/10.1172/jci.insight.127684

In Table 1, the responses given for patients 1 and 6 are incorrect. The correct responses as well as the definition for SCR are below.

Patient 1, SCR

Patient 6, PD

SCR, stringent complete response.

The article has been updated to reflect these changes.

The authors regret the errors.

Version 1. 02/21/2019

Electronic publication

Footnotes


Articles from JCI Insight are provided here courtesy of American Society for Clinical Investigation

RESOURCES